Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Furtmann

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Mini Reviews in Medicinal Chemistry|February 20, 2015
Structural and Modeling Studies on ecto-5'-nucleotidase Aiding in Inhibitor DesignNorbert Furtmann, Jurgen Bajorath
Bioorganic & Medicinal Chemistry|September 10, 2013
Evaluation of molecular model-based discovery of ecto-5'-nucleotidase inhibitors on the basis of X-ray structuresNorbert Furtmann, Jürgen Bajorath
Journal of Medicinal Chemistry|July 23, 2014
Current compound coverage of the kinomeYe Hu, Norbert Furtmann, Jürgen Bajorath
Journal of Medicinal Chemistry|July 24, 2014
Comprehensive analysis of three-dimensional activity cliffs formed by kinase inhibitors with different binding modes and cliff mapping of structural analoguesNorbert Furtmann, Ye Hu, Jürgen Bajorath
Journal of Chemical Information and Modeling|May 23, 2012
Systematic identification and classification of three-dimensional activity cliffsYe Hu, Norbert Furtmann, Michael Gütschow, et al.
Chemical Biology & Drug Design|June 23, 2015
Identification of Interaction Hot Spots in Structures of Drug Targets on the Basis of Three-Dimensional Activity Cliff InformationNorbert Furtmann, Ye Hu, Michael Gütschow, et al.
Journal of Medicinal Chemistry|December 7, 2010
Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitorsMaxim Frizler, Friederike Lohr, Norbert Furtmann, et al.
Drug Discovery Today|May 18, 2024
Best practices for machine learning in antibody discovery and developmentLeonard Wossnig, Norbert Furtmann, Andrew Buchanan, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 3, 2015
Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine ProteasesNorbert Furtmann, Daniela Häußler, Tamara Scheidt, et al.
Journal of Bacteriology|August 24, 2016
Chalcone Isomerase from Eubacterium ramulus Catalyzes the Ring Contraction of FlavanonolsAnnett Braune, Wolfram Engst, Paul W Elsinghorst, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Mini Reviews in Medicinal Chemistry|February 20, 2015
Structural and Modeling Studies on ecto-5'-nucleotidase Aiding in Inhibitor DesignNorbert Furtmann, Jurgen Bajorath
Bioorganic & Medicinal Chemistry|September 10, 2013
Evaluation of molecular model-based discovery of ecto-5'-nucleotidase inhibitors on the basis of X-ray structuresNorbert Furtmann, Jürgen Bajorath
Journal of Medicinal Chemistry|July 23, 2014
Current compound coverage of the kinomeYe Hu, Norbert Furtmann, Jürgen Bajorath
Journal of Medicinal Chemistry|July 24, 2014
Comprehensive analysis of three-dimensional activity cliffs formed by kinase inhibitors with different binding modes and cliff mapping of structural analoguesNorbert Furtmann, Ye Hu, Jürgen Bajorath
Journal of Chemical Information and Modeling|May 23, 2012
Systematic identification and classification of three-dimensional activity cliffsYe Hu, Norbert Furtmann, Michael Gütschow, et al.
Chemical Biology & Drug Design|June 23, 2015
Identification of Interaction Hot Spots in Structures of Drug Targets on the Basis of Three-Dimensional Activity Cliff InformationNorbert Furtmann, Ye Hu, Michael Gütschow, et al.
Journal of Medicinal Chemistry|December 7, 2010
Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitorsMaxim Frizler, Friederike Lohr, Norbert Furtmann, et al.
Drug Discovery Today|May 18, 2024
Best practices for machine learning in antibody discovery and developmentLeonard Wossnig, Norbert Furtmann, Andrew Buchanan, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 3, 2015
Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine ProteasesNorbert Furtmann, Daniela Häußler, Tamara Scheidt, et al.
Journal of Bacteriology|August 24, 2016
Chalcone Isomerase from Eubacterium ramulus Catalyzes the Ring Contraction of FlavanonolsAnnett Braune, Wolfram Engst, Paul W Elsinghorst, et al.
Pageof 4